苏尔巴克坦-杜尔罗巴克坦用于治疗Acinetobacter baumannii-calcoaceticus复合物的治疗
Jordan R Covvey1, Anthony J Guarascio2,3
1Division of Pharmaceutical, Administrative and Social Sciences, Duquesne University School of Pharmacy, Pittsburgh, PA, USA.
Expert review of anti-infective therapy
|September 5, 2024
概括
苏尔布斯坦/杜尔洛巴克坦是一种新的治疗方法,用于治疗Acinetobacter baumannii-calcoaceticus复杂感染. 临床试验表明它是有效的,并且在医院和呼吸机获得的肺炎中具有有利的安全性.
科学领域:
- 传染性疾病 传染性疾病
- 抗微生物耐药性 抗微生物耐药性
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于抗微生物药物的有效性有限,Acinetobacter baumannii-calcoaceticus复合体 (ABC) 感染具有挑战性.
- 由ABC引起的医院和呼吸机肺炎存在重大临床困难.
研究的目的:
- 为提供关于苏尔巴克坦/杜尔罗巴克坦用于治疗ABC感染的综合性审查.
- 讨论其特征,体外活性和临床数据.
主要方法:
- 对制造商的数据进行审查.
- 分析已发表的文献和会议数据.
- 讨论临床试验结果.
主要成果:
- 苏尔布斯坦/杜尔洛巴克坦显示对ABC分离物的功效增强.
- 临床试验和营销后研究显示出积极的临床结果.
- 与替代品相比,该剂具有熟悉和有利的安全概况.
结论:
- 苏尔布斯坦/杜尔洛巴克坦为抗性ABC感染提供了一种新且有效的治疗选择.
- 使用的考虑因素包括组合抗生素治疗,敏感性测试和成本效益.
更多相关视频
05:06Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
555
07:41Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization
Published on: August 4, 2023
3.2K
相关概念视频
Pulmonary Tuberculosis V
174
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
174
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Pneumonia IV: Management
311
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
311
Acute Respiratory Failure-V
125
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
125
